🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525215-13-00
Authorised Phase I

A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

2026-525215-13-00 · tracked via the Priya Life Science EU tracker
Sponsor
F. Hoffmann-La Roche AG
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
07/09/2026
Enrollment target
142
Sites
Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France

Condition studied

Advanced Solid Tumors

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525215-13-00 on CTIS ↗ ← All trials in the EU